ClinicalTrials.gg
CompletedNCT00674609SPRAYUpdated May 3, 2023Results posted

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy

A Phase 3 interventional study of Placebo and Sativex® in Palliative Care, Pain and Cancer, sponsored by Jazz Pharmaceuticals. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing nabiximols in Pain — none open to participants now, none under way, none of them phase 3. nabiximols · Pain.

Enrollment
10th of 17
177 · median 246
Started
2002
with 5 others
Phase 3
15 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
14 of 17
Jazz Pharmaceuticals

Among the 17 studies testing nabiximols in Pain, this one is the 10th largest by enrollment, is one of 6 that started in 2002, is one of 15 in phase 3, and was the 2nd registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

None of the 17 studies testing nabiximols in Pain is open now. The open studies under Pain, anywhere →

About nabiximols

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing nabiximols in Pain as a file.
02

Study summary

The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.

Read the detailed description

This is a two week (two days baseline and two weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex® and GW-2000-02 in subjects with cancer-related pain. Subjects are screened to determine eligibility and completed a two-day baseline period. Subjects then return to the centre for assessment, randomisation and dose introduction. All subjects are allowed to continue using all their current medications, provided that the dose remains stable throughout the study period. Their progress is reviewed after seven to 10 days and at the end of the study (day 14 to 20), or upon withdrawal. Subjects in this study are given the opportunity to be enrolled in an open label extension study (GWEXT0101).

03

Conditions studied

  • Palliative Care
  • Pain
  • Cancer

Keywords

  • Palliative Care
  • Pain
  • Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give .
  • Male or female, age 18 years or above.
  • Diagnosed with cancer of any type, which is considered to be terminal.
  • Diagnosed with cancer-related pain which is not wholly alleviated with their current strong opioid treatment and whose level of pain measured on a NRS is ³four on at least one occasion per day, during the two day run-in period, leading up to visit 1.
  • On strong opioid maintenance therapy for at least seven days prior to the screening visit.
  • Willing to abstain from any use of cannabis during the study, other than the study medication.
  • No cannabinoids use (cannabis, Marinol® or Nabilone) for at least seven days before Visit 1 and willing to abstain from any use of cannabis during the study.
  • Clinically acceptable blood results at the screening visit.
  • Able (in the investigators opinion) and willing to undertake and comply with all study requirements.
  • Willing to allow their own general practitioner, and consultant if appropriate, to be informed of study participation.
  • Willing for the Home Office to be notified of his or her participation in the study (applicable to the UK centres only).

Exclusion criteria

Exclusion Criteria:

  • Know history of substance misuse.
  • Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
  • Received any epidural analgesia within 48 hours prior to study entry.
  • Either received, within two weeks of study entry, or due to receive chemotherapy or radiotherapy during the study.
  • Unable to give .
  • History of any type of schizophrenia, any other psychotic illness, a serious personality disorder, or other significant psychiatric illness other than depression associated with their chronic pain and/or in response to the underlying condition.
  • Currently taking levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
  • Had a serious cardiovascular disorder, including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
  • Significant renal or hepatic impairment, who in the opinion of the investigator, were unsuitable for treatment with study medication.
  • History of epilepsy.
  • Had oral cavity cancers or whose previous treatments had included radiotherapy to the floor of the mouth.
  • Female subjects who were pregnant or lactating or of and were inadequately protected against conception during the study and for three months thereafter.
  • Male subjects who were sexually active and who were not using adequate forms of during the study and for three months thereafter.
  • Subjects who had participated in a clinical research study in the past four weeks, prior to study entry.
  • Planned travel outside the UK during the study (applicable to the UK centres only).
  • Subjects who, in the opinion of the investigator, were unsuitable to participate in the study for any other reason, not mentioned in the entry criteria.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
177 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo control

    Drug: Placebo

  • Experimental
    Sativex

    Active treatment

    Drug: Sativex®

  • Experimental
    THC Alone

    Active treatment

    Drug: THC Alone

Interventions

  • DrugPlacebo

    Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.

    Also known as: GW-4000-01

  • Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.

    Also known as: GW-1000-02

  • Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.

    Also known as: GW-2000-02, THC

06

What researchers measure

Primary outcomes

  1. The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.

    The pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.

    Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)

  2. The Consumption of Escape Analgesic Medication.

    Subjects recorded their use of escape medication each day on their diary card.

    Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)

Secondary outcomes

  1. Sleep Disturbance 0-10 Numerical Rating Scale

    The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.

    Time frame: 2 weeks: baseline to end of week 2 (last 3 days of treatment)

  2. Nausea 0-10 Numerical Rating Scale

    The nausea NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how sick you felt throughout the day?" where 0 = not sick at all and 10 = very sick. A negative value indicates an improvement in nausea score from baseline.

    Time frame: 2 weeks; baseline - end of week 2 (last 3 days of treatment)

  3. Memory 0-10 Numerical Rating Scale

    The memory NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well you are able to remember what you have done in the past 24 hours?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in memory score from baseline.

    Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)

  4. Appetite 0-10 Numerical Rating Scale

    The appetite NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your appetite has been throughout the day?" where 0 = very good and 10 = very poor. A negative value indicates an improvement in appetite score from baseline.

    Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)

  5. Concentration 0-10 Numerical Rating Scale

    The concentration NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well have you been able to concentrate throughout the day e.g. when reading a newspaper?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in concentration score from baseline.

    Time frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment)

  6. EORTC Quality of Life Questionnaire (EORTC-QLQC30)

    Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), a core cancer-specific questionnaire containing 30 items on patients' functioning, global quality of life, disease- and treatment related symptoms. Higher scores indicate a greater degree of symptoms, min.: 0, Max.: 100

    Time frame: 2 weeks; baseline and end of treatment (2 weeks)

  7. Brief Pain Inventory Short Form

    The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). The minimum value is zero and maximum is 10. A higher score represents a poor outcome.

    Time frame: End of 2 weeks

07

Results

Posted Aug 13, 2012

Participant flow

Participant flow — Overall Study
MilestoneSativexTHC AlonePlacebo
Started605859
Completed484551
Not completed12138

Outcome measures

PrimaryThe Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.

The pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.

Time frame:
2 weeks: baseline - end of week 2 (last 3 days of treatment)
Reported as:
Mean · units on a scale
The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.
units on a scaleSativexTHC AlonePlacebo
The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment.-1.32 ± 1.64-0.93 ± 1.15-0.73 ± 1.51
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.014 · Estimated mean treatment difference: -0.67 · 95% CI -1.21 to -0.14
  • THC Alone vs Placebo · ANCOVA · p = 0.244 · Estimated mean treatment difference: -0.32 · 95% CI -0.86 to 0.22
SecondarySleep Disturbance 0-10 Numerical Rating Scale

The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.

Time frame:
2 weeks: baseline to end of week 2 (last 3 days of treatment)
Reported as:
Mean · units on a scale
Sleep Disturbance 0-10 Numerical Rating Scale
units on a scaleSativexTHC AlonePlacebo
Sleep Disturbance 0-10 Numerical Rating Scale-0.59 ± 1.88-0.25 ± 2.33-0.21 ± 1.72
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.346 · Estimated mean treatment difference: -0.31 · 95% CI -0.97 to 0.34
  • THC Alone vs Placebo · ANCOVA · p = 0.95 · Estimated mean treatment difference: 0.02 · 95% CI -0.64 to 0.68
SecondaryNausea 0-10 Numerical Rating Scale

The nausea NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how sick you felt throughout the day?" where 0 = not sick at all and 10 = very sick. A negative value indicates an improvement in nausea score from baseline.

Time frame:
2 weeks; baseline - end of week 2 (last 3 days of treatment)
Reported as:
Mean · units on a scale
Nausea 0-10 Numerical Rating Scale
units on a scaleSativexTHC AlonePlacebo
Nausea 0-10 Numerical Rating Scale0 ± 2.190.27 ± 1.83-0.16 ± 1.25
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.11 · Estimated mean treatment difference: 0.49 · 95% CI -0.11 to 1.09
  • THC Alone vs Placebo · ANCOVA · p = 0.126 · Estimated mean treatment difference: 0.46 · 95% CI -0.13 to 1.05
SecondaryMemory 0-10 Numerical Rating Scale

The memory NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well you are able to remember what you have done in the past 24 hours?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in memory score from baseline.

Time frame:
2 weeks: baseline - end of week 2 (last 3 days of treatment)
Reported as:
Mean · units on a scale
Memory 0-10 Numerical Rating Scale
units on a scaleSativexTHC AlonePlacebo
Memory 0-10 Numerical Rating Scale0.58 ± 2.060.57 ± 1.900 ± 1.35
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.045 · Estimated mean treatment difference: 0.65 · 95% CI 0.01 to 1.28
  • THC Alone vs Placebo · ANCOVA · p = 0.053 · Estimated mean treatment difference: 0.62 · 95% CI -0.01 to 1.25
SecondaryAppetite 0-10 Numerical Rating Scale

The appetite NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your appetite has been throughout the day?" where 0 = very good and 10 = very poor. A negative value indicates an improvement in appetite score from baseline.

Time frame:
2 weeks: baseline - end of week 2 (last 3 days of treatment)
Reported as:
Mean · units on a scale
Appetite 0-10 Numerical Rating Scale
units on a scaleSativexTHC AlonePlacebo
Appetite 0-10 Numerical Rating Scale0.24 ± 2.290.18 ± 1.91-1.65 ± 1.94
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.016 · Estimated mean treatment difference: 0.83 · 95% CI 0.16 to 1.51
  • THC Alone vs Placebo · ANCOVA · p = 0.056 · Estimated mean treatment difference: 0.66 · 95% CI -0.02 to 1.33
SecondaryConcentration 0-10 Numerical Rating Scale

The concentration NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well have you been able to concentrate throughout the day e.g. when reading a newspaper?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in concentration score from baseline.

Time frame:
2 weeks: baseline - end of week 2 (last 3 days of treatment)
Reported as:
Mean · units on a scale
Concentration 0-10 Numerical Rating Scale
units on a scaleSativexTHC AlonePlacebo
Concentration 0-10 Numerical Rating Scale0.26 ± 1.660.22 ± 1.80-0.32 ± 1.39
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.021 · Estimated mean treatment difference: 0.68 · 95% CI 0.10 to 1.25
  • THC Alone vs Placebo · ANCOVA · p = 0.028 · Estimated treatment difference: 0.64 · 95% CI 0.07 to 1.22
SecondaryEORTC Quality of Life Questionnaire (EORTC-QLQC30)

Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), a core cancer-specific questionnaire containing 30 items on patients' functioning, global quality of life, disease- and treatment related symptoms. Higher scores indicate a greater degree of symptoms, min.: 0, Max.: 100

Time frame:
2 weeks; baseline and end of treatment (2 weeks)
Reported as:
Mean · units on a scale
EORTC Quality of Life Questionnaire (EORTC-QLQC30)
units on a scaleSativexTHC AlonePlacebo
EORTC Quality of Life Questionnaire (EORTC-QLQC30)4.93 ± 17.513.57 ± 18.324.74 ± 18.50
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.443 · Estimated mean treatment difference: 2.47 · 95% CI -3.87 to 8.81
  • THC Alone vs Placebo · ANCOVA · p = 0.793 · Estimated mean treatment difference: 0.84 · 95% CI -5.46 to 7.13
SecondaryBrief Pain Inventory Short Form

The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). The minimum value is zero and maximum is 10. A higher score represents a poor outcome.

Time frame:
End of 2 weeks
Reported as:
Mean · units on a scale
Brief Pain Inventory Short Form
units on a scaleSativexTHC AlonePlacebo
Brief Pain Inventory Short Form0.2 ± 5.63-3.38 ± 6.430.41 ± 5.55
Statistical analysis
  • Sativex vs Placebo · ANCOVA · p = 0.619 · Estimated mean treatment difference: -1.04 · 95% CI -5.23 to 3.15
  • THC Alone vs Placebo · ANCOVA · p = 0.048 · Estimated mean treatment difference: -4.07 · 95% CI -8.10 to -0.05
PrimaryThe Consumption of Escape Analgesic Medication.

Subjects recorded their use of escape medication each day on their diary card.

Time frame:
2 weeks: baseline - end of week 2 (last 3 days of treatment)
Reported as:
Mean · tablets per day
The Consumption of Escape Analgesic Medication.
tablets per daySativexTHC AlonePlacebo
The Consumption of Escape Analgesic Medication.0.72 ± 0.8210.88 ± 0.8520.68 ± 0.662
Statistical analysis
  • Sativex vs Placebo · Regression, Logistic · p = 0.688 · Estimated mean treatment difference: -0.04 · 95% CI -0.25 to 0.16
  • THC Alone vs Placebo · Regression, Logistic · p = 0.899 · Estimated mean treatment difference: 0.01 · 95% CI -0.19 to 0.22

Adverse events

Collected over All adverse events (AEs) occurring from the time of consent to post study follow up (14 - 20 days) were collected. All deaths and serious adverse events (SAEs) occurring within 28 days of the final dose of study medication were also collected.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sativex—13/60 (21.7%)51/60 (85%)
THC Alone—13/58 (22.4%)45/58 (77.6%)
Placebo—7/59 (11.9%)44/59 (74.6%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventSativexTHC AlonePlacebo
Neoplasm progression nosNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/605/582/59
Metastases to brainNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/602/580/59
SomnolenceNervous system disorders1/602/581/59
ConfusionPsychiatric disorders0/602/581/59
Cardio-respiratory arrestCardiac disorders0/600/582/59
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/600/582/59
Urinary retentionRenal and urinary disorders2/600/580/59
Gastric ulcer haemorrhageGastrointestinal disorders0/601/580/59
NauseaGastrointestinal disorders0/601/580/59
Disease progression nosGeneral disorders1/601/580/59
Most frequent other events
Showing 10 of 18
Most frequent other events
EventSativexTHC AlonePlacebo
SomnolenceNervous system disorders9/608/588/59
DizzinessNervous system disorders7/607/583/59
NauseaGastrointestinal disorders7/606/586/59
ConstipationGastrointestinal disorders3/600/586/59
Neoplasm progression NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/605/583/59
Oral painGeneral disorders0/605/583/59
GlossodyniaGeneral disorders0/605/580/59
Gamma-glutamyltransferase increasedInvestigations0/605/583/59
VomitingGastrointestinal disorders5/604/584/59
ConfusionPsychiatric disorders4/600/582/59

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)SativexTHC AlonePlaceboTotal
<=18 years0000
Between 18 and 65 years393838115
>=65 years21202162
Age, Continuous
Age, Continuous(years)SativexTHC AlonePlaceboTotal
Mean59.4 ± 12.0861.3 ± 12.560.1 ± 12.3160.2 ± 12.25
Sex: Female, Male
Sex: Female, Male(Participants)SativexTHC AlonePlaceboTotal
Female27282782
Male33303295
Region of Enrollment
Region of Enrollment(participants)SativexTHC AlonePlaceboTotal
United Kingdom22182161
Belgium44311
Romania343635105
08

Study locations

1 site
  • Shropshire and Mid-Wales Hospice
    Shrewsbury, SY3 8HS, United Kingdom
09

References and documents

Publications

  • Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010 Feb;39(2):167-79. doi: 10.1016/j.jpainsymman.2009.06.008. Epub 2009 Nov 5. PubMed 19896326 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Feb 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 8 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2008
First posted
May 8, 2008
Start
Feb 2002
Primary completionActual
Feb 2004
CompletionActual
Mar 2004
Results first posted
Aug 13, 2012
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00674609
First posted
May 8, 2008
Start date
Feb 2002
Primary completion
Feb 2004
Completion
Mar 2004
Results posted
Aug 13, 2012
Last update
May 3, 2023

Study contacts

Jeremy R Johnson, MB ChB
principal investigator · Shropshire and Mid-Wales Hospice

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nabiximols · Dronabinol

Start the discussion